| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ofatumumab |
| Brand | Arzerra® |
| Indication | For the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab. |
| Assessment Process | |
| Rapid review commissioned | 01/06/2010 |
| Rapid review completed | 22/06/2010 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.